Febuxostat added to mesalamine for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether adding febuxostat, a medicine usually used for gout, can help reduce inflammation in people with mild to moderate ulcerative colitis who are already taking mesalamine. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mild or moderate ulcerative colitis, confirmed by a scope test.
- You are currently taking mesalamine (5-ASA) for your colitis.
- You do not have severe or complicated ulcerative colitis.
- You have not had surgeries to remove part or all of your colon.
- You are not pregnant or breastfeeding.
- You do not have significant liver or kidney problems, diabetes, heart disease, or other serious conditions.
- You do not have an allergy to febuxostat or mesalamine.
- You are not on steroids, immunosuppressants, or biologic therapies.
- You do not have alcohol or drug addiction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study compares taking tofacitinib alone versus combining it with mesalamine to keep ulcerative colitis under control. If you are currently in remission, this trial may help find the best way to prevent flare-ups.
This study tests whether a special fibre supplement can reduce inflammation in people with active ulcerative colitis. You take the supplement daily for a few weeks, and researchers check how it affects your symptoms and gut health.
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.